Steven Cohen’s Rhythm Pharmaceuticals RYTM Stock Holding History

Steven Cohen’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46M	Sell	414,210 -432,591	-51%	-$39.1M	0.05%	468
2026 Q1	$73.6M	Buy	846,801 +417,381	+97%	+$40.6M	0.09%	242
2025 Q4	$46M	Buy	+429,420	New	+$45.6M	0.05%	444
2025 Q3	–	Sell	-170,832	Closed	-$10.8M	–	2633
2025 Q2	$10.8M	Buy	170,832 +106,990	+168%	+$6.55M	0.02%	705
2025 Q1	$3.38M	Buy	+63,842	New	+$3.54M	0.01%	1081
2023 Q4	–	Sell	-4,146	Closed	-$95K	–	2729
2023 Q3	$95K	Buy	+4,146	New	+$92.8K	﹤0.01%	1978
2023 Q2	–	Sell	-11,955	Closed	-$213K	–	2706
2023 Q1	$213K	Buy	+11,955	New	+$300K	﹤0.01%	1464
2018 Q2	–	Sell	-180,000	Closed	-$3.58M	–	1155
2018 Q1	$3.58M	Buy	180,000 +100,000	+125%	+$2.66M	0.02%	644
2017 Q4	$2.33M	Buy	+80,000	New	+$2.12M	0.01%	711

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Steven Cohen's RYTM Position: Q2 2026 in Review

Steven Cohen reduced its Rhythm Pharmaceuticals (RYTM) stake by 51% in Q2 2026, selling an estimated $39.1M and leaving 414,210 shares worth $46M. The position accounts for 0.05% of the portfolio, ranked #468.

Steven Cohen first reported a position in RYTM in Q4 2017 and has held it in 9 quarters since. The position peaked at $73.6M in Q1 2026. 300 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Steven Cohen held 414,210 shares of Rhythm Pharmaceuticals worth $46M as of Q2 2026.
Steven Cohen sold 432,591 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $39.1M.
Rhythm Pharmaceuticals made up 0.05% of Steven Cohen's portfolio in Q2 2026, its #468 holding.
Steven Cohen first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 9 quarters since.
Steven Cohen's Rhythm Pharmaceuticals position peaked at $73.6M in Q1 2026.
300 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.